From: Exosomal noncoding RNAs in Glioma: biological functions and potential clinical applications
NcRNA Canditates | Source of exosome | Exosome isolation techniques | System | Biomarker potential | Reference |
---|---|---|---|---|---|
miR-21 | CSF | Ultracentrifugation | GBM | A biomarker for GBM diagnosis | [109] |
miR-21 | CSF & serum | Ultracentrifugation | Glioma | A biomarker for glioma diagnosis and prognosis | [110] |
miR-151a | CSF & serum | Ultracentrifugation | GBM | Predict prognosis of GBM patients | [76] |
miR-320 & miR-574-3p | Serum | Precipitation method | GBM | A biomarker for GBM diagnosis | [108] |
miR-221 | Serum | Precipitation method | Glioma | A biomarker for glioma diagnosis and grade prediction | [62] |
miR-21, miR-222 & miR-124-3p | Serum | PEG-based method | Glioma | A biomarker for glioma diagnosis and grade prediction | [104] |
miR-301a | Serum | Precipitation method | Glioma | Serve as diagnostic and prognostic biomarker | [105] |
miR-148a | Serum | Precipitation method | GBM | A biomarker for GBM diagnosis | [63] |
miR-454-3p | Serum | Immunoaffinity capture | Glioma | A biomarker for glioma diagnosis | [106] |
lncRNA-HOTAIR | Serum | Precipitation method | GBM | A biomarker for GBM diagnosis | [107] |
lncRNA-SBF2-AS1 | Serum | Ultracentrifugation | GBM | Serve as diagnostic biomarker for therapy-refractory GBM | [77] |